Financial Performance - The company's operating revenue for the first half of 2022 was CNY 407,389,669.31, representing a 20.59% increase compared to CNY 337,822,043.33 in the same period last year[21]. - The net profit attributable to shareholders decreased by 23.09% to CNY 17,369,678.22 from CNY 22,583,211.17 in the previous year[21]. - The net profit after deducting non-recurring gains and losses fell by 42.83% to CNY 15,947,634.58 compared to CNY 27,892,749.03 in the same period last year[21]. - The basic earnings per share decreased by 24.04% to CNY 0.0278 from CNY 0.0366 in the same period last year[21]. - The weighted average return on net assets was 1.80%, down from 2.31% in the previous year[21]. - The company achieved a total revenue of 407.39 million yuan, representing a year-on-year growth of 20.59%[36]. - The net profit attributable to shareholders was 17.37 million yuan, a decline of 23.09% year-on-year, largely due to decreased sales in the pharmaceutical sector[37]. - The company reported a net profit margin improvement, with undistributed profits rising from CNY 182,259,993.72 to CNY 199,629,671.94, an increase of 9.5%[139]. - The net profit for the first half of 2022 was CNY 15,271,333.98, down 32.8% from CNY 22,737,455.22 in the same period of 2021[146]. - The operating profit for the first half of 2022 was CNY 19,004,077.48, a decline of 31.6% from CNY 27,844,729.92 in the first half of 2021[145]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to CNY 37,811,459.99, a 178.70% increase from a negative CNY 48,044,082.93 in the previous year[21]. - Cash inflow from operating activities was CNY 390,256,922.38 in the first half of 2022, compared to CNY 368,152,305.12 in the same period of 2021[150]. - Total cash outflow from investment activities reached ¥205,371,091.69, resulting in a net cash flow from investment activities of -¥200,891,423.69, compared to -¥99,244,742.63 in the previous year[152]. - Cash inflow from financing activities amounted to ¥79,170,000.00, while cash outflow totaled ¥64,479,701.63, leading to a net cash flow from financing activities of ¥14,690,298.37, up from ¥956,394.36 in 2021[152]. - The total cash and cash equivalents at the end of the period were ¥125,559,704.08, down from ¥232,839,826.61 at the end of the first half of 2021[152]. Business Segments and Operations - The pharmaceutical business revenue was 171.62 million yuan, a decrease of 30.08% year-on-year, primarily due to the impact of COVID-19 on major sales regions[36]. - The steel structure business saw a revenue increase of 76.94%, reaching 149.52 million yuan, driven by enhanced team incentives and resource integration[36]. - The newly acquired blue light mineral water beverage business contributed an additional revenue of 73.36 million yuan[36]. - The health industry segment saw a remarkable revenue increase of 2,354.00%, reaching CNY 71,086,909.03, compared to CNY 2,896,773.28 in the same period last year[47]. - The company is expanding its health product offerings by acquiring mineral water resources to diversify its business and reduce risks associated with the pandemic[72]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,100,454.29, up 4.07% from CNY 1,351,112,420.20 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 0.98% to CNY 966,940,039.73 from CNY 976,494,790.70 at the end of the previous year[21]. - Current liabilities increased to CNY 377,130,317.46, compared to CNY 327,550,537.98, marking a rise of 15.1%[139]. - Non-current liabilities totaled CNY 60,157,146.38, up from CNY 42,125,873.69, indicating a significant increase of 42.8%[139]. - The total liabilities at the end of the period were CNY 1,872,950, reflecting the company's leverage position[162]. Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has maintained its board and management personnel without changes during the reporting period, ensuring stability in governance[78]. - The company has a systematic approach to environmental monitoring, including third-party assessments of wastewater and air emissions every six months[88]. - The company has maintained a strong commitment to shareholder rights, ensuring timely and accurate information disclosure and facilitating shareholder participation in decision-making processes[91]. - Employee rights are prioritized, with compliance to labor laws, timely salary payments, and regular health checks to ensure a safe working environment[92]. Research and Development - The company is focusing on the development of new products based on existing advantages in therapeutic areas, particularly for its core products[33]. - The company aims to enhance its R&D capabilities by collaborating with domestic and international research institutions to adapt to changing market demands and improve product acceptance[73]. - Research and development expenses increased to CNY 13,364,976.44 in the first half of 2022, up 36.5% from CNY 9,818,160.05 in the first half of 2021[145]. Environmental and Social Responsibility - The company has achieved compliance with environmental standards, with all major pollutants from wastewater and exhaust gases meeting regulatory limits, including COD at 129 mg/L against a limit of 500 mg/L and VOCs at 2.29 mg/m³ against a limit of 60 mg/m³[83][84]. - The company has received recognition for its environmental efforts, including being rated as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for 2021[90]. - The company emphasizes its commitment to social responsibility and actively supports education and scientific research in China[93]. - The company donated 3 million RMB to Chengdu University of Traditional Chinese Medicine for the "Double First-Class" initiative in October 2021, ensuring effective use of funds for talent cultivation and technology research[93]. Acquisitions and Investments - The company acquired 100% equity in Sichuan Blue Light Mineral Water Co., Ltd. for 61,000,000.00 yuan, effective January 1, 2022[55]. - The company also acquired 100% equity in Chengdu Yuanhong Mineral Water Co., Ltd. for 33,200,000.00 yuan, effective June 30, 2022[55]. - The company reported an investment amount of 108,200,000.00 yuan for the reporting period, a significant increase of 9,362.32% compared to 1,143,483.00 yuan in the same period last year[53]. Risks and Challenges - The company has identified risks related to drug price reductions due to government policies, which could adversely affect sales and overall operations[69]. - The company emphasizes a cautious approach to new business development, prioritizing risk control and market demand alignment[74].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 206,595,617.51, representing a 39.11% increase compared to CNY 148,511,424.02 in the same period last year[3]. - The net profit attributable to shareholders decreased by 19.48% to CNY 9,433,788.66 from CNY 11,715,714.45 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 33.59% to CNY 9,230,154.56, down from CNY 13,899,723.69[3]. - The net profit for the first quarter was CNY 8,621,028.17, compared to CNY 11,865,391.51 in the same period last year, reflecting a decrease of approximately 27%[18]. - The basic and diluted earnings per share were both CNY 0.0151, compared to CNY 0.0187 in the previous period, indicating a decrease of 19.3%[19]. - The total comprehensive income attributable to the parent company was CNY 9,433,788.66, down from CNY 11,715,714.45, reflecting a decline of 19.5%[19]. Cash Flow - The net cash flow from operating activities increased by 134.17% to CNY 19,660,473.69, compared to a negative cash flow of CNY 57,536,200.29 in the previous year[3]. - Cash inflows from operating activities totaled CNY 223,148,429.87, an increase of 14.1% from CNY 195,544,500.14 in the previous period[21]. - The net cash flow from investing activities was negative CNY 191,086,908.94, worsening from negative CNY 87,370,886.71 in the previous period[21]. - The cash and cash equivalents at the end of the period were CNY 129,570,886.12, down from CNY 234,189,880.71 at the end of the previous period, reflecting a decrease of 44.7%[22]. - The company reported a cash inflow from financing activities of CNY 27,659,959.66, with cash inflows from borrowings amounting to CNY 28,020,000.00[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,259,884.96, a 7.57% increase from CNY 1,307,282,000.53 at the end of the previous year[3]. - The company’s total liabilities increased to CNY 416,751,257.23 from CNY 327,644,146.36, reflecting a growth of about 27%[16]. - The company’s equity attributable to shareholders rose to CNY 986,261,207.17 from CNY 975,577,673.12, an increase of approximately 1.3%[16]. Research and Development - The company reported a significant increase in R&D expenses by 245.61%, amounting to CNY 506.92 million, due to increased investment in research and development[8]. - The company reported a significant increase in research and development expenses, which rose to CNY 7,133,097.95 from CNY 2,063,937.22, marking an increase of about 246%[18]. Expenses - The total operating costs amounted to CNY 196,927,814.86, up from CNY 130,601,415.61, indicating a year-over-year increase of about 51%[18]. - The company experienced a 41.40% decrease in selling expenses, totaling CNY 2,366.31 million, attributed to reduced marketing expenditures in the pharmaceutical sector[8]. Investments - The company acquired two subsidiaries, resulting in the recognition of goodwill due to the purchase price exceeding the fair value of identifiable net assets[7]. - The company plans to invest up to CNY 130 million in the construction of a health management center in Haikou, with a property area of approximately 7,960 square meters[12]. Other - The first quarter report was not audited, indicating that the financial figures are subject to further verification[23].

Financial Performance - The company's operating revenue for 2021 was CNY 945,317,490.17, representing a 24.50% increase compared to CNY 759,307,481.01 in 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 70,321,594.57, an increase of 87.51% from CNY 37,503,531.51 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 70,286,853.72, up 50.08% from CNY 46,834,417.52 in 2020[20]. - The basic earnings per share for 2021 was CNY 0.11, an increase of 83.33% compared to CNY 0.06 in 2020[20]. - The total assets at the end of 2021 were CNY 1,307,282,000.53, a 14.67% increase from CNY 1,140,012,121.38 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were CNY 975,577,673.12, reflecting a 6.97% increase from CNY 912,050,796.35 in 2020[20]. - The net cash flow from operating activities for 2021 was negative CNY 55,640,088.39, a decrease of 512.28% compared to positive CNY 13,495,800.83 in 2020[20]. - The weighted average return on net assets for 2021 was 7.45%, up from 4.15% in 2020[20]. - The company achieved a total revenue of 945.32 million yuan in 2021, representing a year-on-year growth of 24.50%[52]. - The net profit attributable to shareholders was 70.32 million yuan, an increase of 87.51% year-on-year, while the net profit after deducting non-recurring gains and losses was 70.29 million yuan, up 50.08%[52]. Market Position and Growth - The Chinese pharmaceutical market grew by 12.3% in 2021, with traditional Chinese medicine (TCM) revenue reaching ¥4,862 billion, reflecting a robust growth trend[30]. - The company holds a strong position in the TCM market, with its core product, Sanqi Tongshu Capsule, ranking fourth in sales among oral TCM for cerebrovascular diseases in urban public hospitals[32]. - The company plans to enhance its R&D efforts in new products and technologies to adapt to the evolving pharmaceutical landscape and competitive pressures[30]. - The company aims to enhance its market position by focusing on health and life quality improvement, aligning with the "Healthy China" strategy[45]. - The company is focused on building a comprehensive health management solution to meet the increasing health awareness and consumption demands of the public[92]. - The company aims to establish dual headquarters in Chengdu and Hainan by 2025, focusing on creating a national health industry ecosystem[94]. - The company plans to enhance its pharmaceutical business by optimizing channel resources and expanding clinical and OTC channels[98]. Research and Development - The company holds 105 authorized patents, including 27 invention patents and 4 international patents, showcasing its strong R&D capabilities[47]. - The company completed 30 new patent applications and received 20 authorized patents in 2021, reflecting its commitment to innovation and R&D[54]. - The company emphasizes R&D in traditional Chinese medicine modernization and biomedicine, aiming to accelerate the development of new products and technologies[41]. - The company is focusing on developing new products such as the "Sanqi Tongshu Capsule" and "Biyuan Shuqing Oral Liquid" to enhance market presence and clinical value[72][73]. - Research and development investments increased by 20% in 2021, totaling 100 million yuan, focusing on innovative technologies[123]. Operational Efficiency - The company implemented a performance management system that resulted in a 19.93% increase in employee efficiency compared to 2020[55]. - The company has established a modern Chinese medicine production line that integrates advanced production technologies and real-time quality monitoring, enhancing production efficiency and product quality[48]. - The company has established a sound corporate governance structure in compliance with the requirements of the Company Law and the Guidelines for Corporate Governance of Listed Companies[106]. - The company has implemented strict internal control measures to ensure effective operation and compliance[106]. - The company has established independent financial institutions with a comprehensive accounting system and financial management policies[108]. Risks and Challenges - The company faces potential risks including drug price reductions, COVID-19 impacts, and new product development challenges[5]. - The company faces risks from potential drug price reductions due to regulatory changes and market conditions[102]. - Ongoing COVID-19 pandemic risks may impact hospital operations and project timelines, affecting overall revenue[102]. Corporate Governance and Social Responsibility - The company has established various committees under the board of directors to enhance governance, including a strategy committee and an audit committee[106]. - The company maintains a commitment to timely and accurate information disclosure to support investor decision-making[106]. - The company has been recognized as a "Green Enterprise" by the Sichuan Provincial Department of Ecology and Environment for multiple years, indicating strong environmental compliance[167]. - The company has conducted regular environmental monitoring and audits, with third-party assessments confirming compliance with environmental regulations[166]. - The company emphasizes the protection of shareholder rights by ensuring timely and accurate information disclosure, allowing equal access to information for all shareholders[168]. Employee and Management - The company employed a total of 647 staff members, with 352 in the parent company and 295 in major subsidiaries[134]. - The company has a competitive salary policy to attract and retain talent, with a focus on short, medium, and long-term incentive plans[136]. - The company has implemented a robust employee training program to enhance skills and improve work quality[169]. - The company is focused on strategic growth through the recruitment of experienced executives from various sectors[119]. Future Outlook - The company aims for a net profit of no less than 125% of the 2021 figure for 2022, excluding stock payment expenses due to equity incentives[98]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales channels by the end of 2022[121]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025[122]. - The company intends to introduce strategic investors and establish an industrial merger fund to accelerate acquisition speed and reduce market risks[99].

Financial Performance - The company's operating revenue for Q3 2021 was ¥211,495,672.05, a decrease of 4.63% compared to the same period last year[3] - Net profit attributable to shareholders was ¥11,733,667.15, an increase of 41.44% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,012,346.90, down 18.26% from the previous year[3] - Basic earnings per share for the period were ¥0.0190, up 40.74% compared to the same period last year[3] - Total operating revenue for Q3 2021 was CNY 546,420,942.10, an increase from CNY 534,031,162.03 in the previous period[22] - Net profit for Q3 2021 reached CNY 38,976,010.50, up from CNY 30,846,841.36 in the same period last year, representing a growth of approximately 26.5%[23] - The company reported a basic earnings per share of CNY 0.0631, compared to CNY 0.0500 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,231,892,652.77, reflecting an increase of 8.06% from the end of the previous year[4] - The company's total assets increased to CNY 1,231,892,652.77 from CNY 1,140,012,121.38 year-over-year[20] - Total liabilities rose to CNY 285,626,725.86, compared to CNY 227,558,599.33 in the previous period[20] - The total non-current assets amounted to CNY 381,417,275.53, an increase from CNY 273,950,052.58 year-over-year[20] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥65,569,615.26, a significant decline of 841.83% year-to-date[3] - The company's cash flow from operating activities was CNY 499,877,777.94, down from CNY 518,732,406.74 in the previous period[26] - The net cash flow from operating activities was -65,569,615.26 CNY, compared to -6,961,921.94 CNY in the previous year, indicating a significant decline[27] - Total cash inflow from operating activities amounted to 535,412,335.10 CNY, while cash outflow was 600,981,950.36 CNY, resulting in a net cash outflow of 65,569,615.26 CNY[27] - Cash flow from investment activities showed a net outflow of -96,156,587.60 CNY, compared to -29,509,688.98 CNY in the same period last year[28] - The company received 16,000,000.00 CNY from financing activities, with a net cash inflow of 9,102,167.16 CNY after accounting for outflows[28] Expenses - The company’s management expenses increased by 34.38% to ¥39,872,019.71, mainly due to costs associated with the health industry project[11] - The company’s financial expenses decreased by 65.49% to -¥2,025,443.04, attributed to a reduction in bank deposits leading to lower interest income[11] - Research and development expenses for Q3 2021 were CNY 13,535,458.12, a decrease from CNY 18,160,280.09 in the previous period[23] - Cash paid for purchasing goods and services increased by 45.38% to CNY 280,983,278.43, due to preemptive stockpiling in response to rising raw material prices[12] - The company paid 65,620,900.58 CNY to employees, an increase from 53,600,183.60 CNY in the previous year[27] Shareholder Information - The company’s major shareholder, Sichuan Huasheng Group, holds 18.08% of shares, with 89,033,593 shares pledged[14] - The company terminated its non-public offering of A-shares, which was pending approval from the China Securities Regulatory Commission[16] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 641.59% to ¥49,330,777.54, primarily due to advance payments for steel structure project materials[8] - Investment income increased by 100.41% to CNY 899,729.08, primarily due to the recognition of investment losses from the previous year[12] - Credit impairment losses rose by 153.46% to CNY 3,286,671.55, mainly due to the recovery of receivables[12] - Total current assets decreased to CNY 850,475,377.24 from CNY 866,062,068.80, indicating a decline in liquidity[18] - Cash and cash equivalents decreased to CNY 253,630,835.90 from CNY 405,151,171.60, showing a significant reduction in cash reserves[18] - Inventory increased to CNY 97,415,329.00 from CNY 75,842,157.21, indicating a buildup of stock[18] - The company did not undergo an audit for the third quarter report[29] - The company has not applied the new leasing standards for the financial statements[29]

证券代码：000790 证券简称：华神科技 公告编号：2021-073 成都华神科技集团股份有限公司 关于参加2021年四川辖区上市公司 投资者集体接待日的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解公司情况，就公司治理及社会责任 /ESG、经营状况、发展战略、风险防控、市值管理、投资者保护等投资者所关 心的问题，公司定于 2021 年 9 月 16 日 15:00-17:00 参加由四川省上市公司协会 联合深圳市全景网络有限公司举办的主题为"守初心担使命 为投资者办实 事"2021 年四川辖区上市公司投资者网上集体接待日活动。现将有关事项公告如 下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net 进入专区 页面参与交流。 出席本次集体接待日的人员有：公司董事长、总裁黄明良先生；财务总监李 俊先生；董事会秘书刁海雷先生。 欢迎广大投资者积极参与。 特此公告。 成都华神科技集团股份有限公司 董事会 二〇二一年九月十四日 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥334,925,270.05, representing a 7.25% increase compared to ¥312,273,442.44 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was ¥27,170,249.27, a 20.48% increase from ¥22,550,767.77 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥32,227,215.21, reflecting a 24.89% increase from ¥25,803,802.83 year-on-year[21]. - The basic earnings per share for the first half of 2021 was ¥0.0441, up 20.49% from ¥0.0366 in the same period last year[21]. - The total operating revenue for the reporting period was CNY 334,925,270.05, representing a year-on-year increase of 7.25% compared to CNY 312,273,442.44 in the same period last year[41]. - The company reported a total profit of ¥31,647,913.10 for the first half of 2021, compared to ¥25,483,827.24 in the first half of 2020, representing an increase of approximately 24.5%[135]. - The company reported a net profit increase, with retained earnings rising to CNY 159,761,577.21 from CNY 138,754,933.58, an increase of approximately 15.1%[127]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,178,038,023.04, a 3.34% increase from ¥1,140,012,121.38 at the end of the previous year[21]. - The total liabilities increased to CNY 243,423,613.31 from CNY 227,558,599.33, representing a rise of about 6.9%[127]. - The company's total equity reached CNY 934,614,409.73, up from CNY 912,453,522.05, indicating an increase of approximately 2.0%[127]. - The company's cash and cash equivalents decreased significantly to CNY 129,195,348.83 from CNY 269,702,162.44, a decline of about 52.0%[129]. - The company's accounts receivable stood at CNY 239,448,582.32, representing 20.33% of total assets, down 1.59% from the previous year[47]. - The company's inventory was valued at CNY 65,374,083.39, which is a decrease of 1.10% from CNY 75,842,157.21 in the previous year[47]. Cash Flow - The net cash flow from operating activities was negative at -¥46,328,881.46, a decline of 173.13% compared to -¥16,962,117.57 in the same period last year[21]. - The cash flow from investment activities showed a net outflow of -CNY 95,433,434.42, compared to a net inflow of CNY 3,822,523.79 in the first half of 2020[145]. - The total cash outflow from operating activities reached CNY 409,991,732.70, up 13.8% from CNY 360,336,938.61 in the previous year[144]. - The cash outflow for purchasing goods and services was CNY 171,456,507.89, which is a significant increase from CNY 126,281,336.32 in the first half of 2020[142]. Business Segments - The pharmaceutical manufacturing segment generated revenue of 245,448,400 CNY, a slight decrease of 2.73% year-on-year due to domestic medical insurance cost control and centralized procurement policies[33]. - The construction steel structure business saw revenue increase by 54.96% year-on-year, reaching 84,502,600 CNY, driven by enhanced market expansion and project implementation[33]. - The pharmaceutical manufacturing sector generated CNY 245,448,353.80, accounting for 73.28% of total revenue, but saw a decline of 2.73% from CNY 252,333,096.27[41]. Research and Development - The company obtained 13 authorized patents during the reporting period, enhancing its research and development capabilities[31]. - The company plans to enhance its research and development efforts, focusing on modern traditional Chinese medicine and biotechnology, to drive product innovation and market expansion[62]. - Research and development expenses rose to ¥9,818,160.05 in the first half of 2021, compared to ¥7,400,455.98 in the first half of 2020, an increase of approximately 32.5%[134]. Environmental Compliance - The company has been recognized as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for three consecutive years (2018-2020)[77]. - The company has a complete wastewater treatment system and a corresponding exhaust gas treatment system, ensuring compliance with environmental standards[72]. - The company has established an emergency response plan for environmental incidents and conducts regular drills[74]. Corporate Governance - The company held three shareholder meetings during the reporting period, with investor participation rates of 25.51%, 18.95%, and 19.92% respectively[65]. - The company has appointed new executives, including a new Chief Financial Officer and Executive Vice President, during the reporting period[66]. - The financial report was approved by the board of directors on August 27, 2021[175]. Future Outlook - The company plans to continue expanding its market presence and invest in new technologies[159]. - The company is in the process of a non-public offering of A-shares, pending approval from the China Securities Regulatory Commission[104].

Financial Performance - The company's operating revenue for 2020 was CNY 759,307,481.01, representing a 1.87% increase compared to CNY 745,340,799.08 in 2019[18]. - The net profit attributable to shareholders for 2020 was CNY 37,503,531.51, a decrease of 39.15% from CNY 61,632,302.42 in 2019[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,834,417.52, down 22.81% from CNY 60,677,086.08 in the previous year[18]. - The net cash flow from operating activities was CNY 13,495,800.83, a significant decline of 79.25% compared to CNY 65,027,238.40 in 2019[18]. - Basic earnings per share for 2020 were CNY 0.06, a decrease of 40.00% from CNY 0.10 in 2019[18]. - The diluted earnings per share for 2020 was CNY 0.06, a decrease of 40.00% compared to CNY 0.10 in 2019[19]. - The weighted average return on equity was 4.15%, down from 7.11% in the previous year, reflecting a decline of 2.96%[19]. - Total assets at the end of 2020 amounted to CNY 1,140,012,121.38, a slight increase of 0.13% from CNY 1,138,495,537.52 at the end of 2019[19]. - Net assets attributable to shareholders increased by 3.56% to CNY 912,050,796.35 from CNY 880,710,870.48 in 2019[19]. - The company reported a total operating income of CNY 225,276,318.98 in Q4 2020, with a total annual operating income of CNY 759,307,480.01[22]. Revenue Breakdown - The pharmaceutical manufacturing business experienced a revenue decline of 12.72%, totaling CNY 565.53 million, due to the impact of the COVID-19 pandemic[37]. - The construction steel structure business saw a significant revenue increase of 110.28%, reaching CNY 178.15 million, driven by enhanced market expansion and project acquisition[37]. - Revenue from the pharmaceutical manufacturing sector decreased by 12.72% to CNY 565,534,191.68, accounting for 74.48% of total revenue[41]. - The sales volume of traditional Chinese and Western medicine products was 20,552,578 boxes, down 20.47% from 25,841,925 boxes in 2019[44]. - The company’s revenue from biological pharmaceuticals dropped by 38.45% to CNY 4,404,836.42[41]. Cash Flow and Investments - The company reported a significant decrease in cash flow, indicating potential challenges in operational efficiency[18]. - The net cash flow from operating activities was 13.50 million yuan, down 79.25% year-on-year[77]. - Investment cash flow net amount decreased by 533.38% to -¥29.94 million in 2020 from ¥6.91 million in 2019, driven by increased cash payments for financial assets[55]. - The company reported a significant increase in cash outflows for operating activities, primarily due to increased payments for materials and subcontracting[55]. Research and Development - The company continues to focus on high-tech product development and production, as well as traditional Chinese and Western medicine production[17]. - The company holds 28 invention patents, including 4 international patents, and has made significant advancements in research and development, particularly in modern traditional Chinese medicine[31]. - The company plans to increase R&D investment in biomedicine, modern traditional Chinese medicine, and stem cell fields, aiming to enhance product competitiveness and expand its product pipeline[78]. - The number of R&D personnel increased by 23.85% to 161 in 2020 from 130 in 2019, representing 22.77% of total staff[53]. Corporate Governance and Compliance - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management[5]. - The company has not made any changes to its accounting data that require retrospective adjustments or restatements[18]. - The company has established a comprehensive performance evaluation and incentive mechanism for senior management to enhance management effectiveness[188]. - The company maintained a 100% inclusion rate for both total assets and operating income in its internal control evaluation[189]. - The audit opinion for the financial statements was a standard unqualified opinion, indicating compliance with accounting standards[196]. Shareholder and Dividend Information - The company plans to distribute a cash dividend of CNY 0.1 per 10 shares to all shareholders, based on a total of 616,360,564 shares[6]. - The cash dividend policy for 2020 includes a distribution of 0.10 yuan per 10 shares (before tax), with no bonus shares issued, maintaining a total share capital of 616,360,564 shares[85][86]. - The cash dividend for 2019 was also 0.10 yuan per 10 shares (before tax), consistent with the previous year, reflecting a stable dividend policy[86]. - The company distributed a cash dividend of CNY 0.1 per 10 shares, totaling CNY 6,163,605.64, which accounted for 100% of the profit distribution[90]. Environmental and Social Responsibility - The company donated a total of 5.1632 million RMB to support pandemic relief efforts during the reporting period[132]. - The company achieved a 75% reduction in nitrogen oxide emissions after the boiler low-nitrogen transformation in 2019[134]. - The company has established a complete wastewater treatment system and a corresponding waste gas treatment system, ensuring compliance with environmental standards[134]. - The company has implemented a comprehensive pollution control and recycling system for wastewater, waste gas, noise, and solid waste[134]. Management and Leadership Changes - The company experienced a leadership transition with the election of several new directors on May 8, 2020, including Huang Mingliang as chairman and president[163]. - The company reported a significant change in management due to a change in actual control, with multiple directors and executives resigning on March 30, 2020[161]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic leadership changes and new appointments[162]. Future Outlook and Strategic Initiatives - The company aims to achieve a net profit for 2020 that is no less than 120% of the 2019 figure[77]. - The company is focusing on building a regional health industry ecosystem centered around major urban clusters in China[75]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[166]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[166].

成都华神科技集团股份有限公司 2021 年第一季度报告全文 成都华神科技集团股份有限公司 2021 年第一季度报告 2021-034 2021 年 04 月 1 成都华神科技集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄明良、主管会计工作负责人王晓梅及会计机构负责人(会计主 管人员)郭婷声明：保证季度报告中财务报表的真实、准确、完整。 2 成都华神科技集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 148,511,424.02 | 129,229,750.18 | 14.92% | | 归属于上市公司股东的净利润（元 ...

Financial Performance - The company's operating revenue for 2020 was CNY 759,307,481.01, representing a 1.87% increase compared to CNY 745,340,799.08 in 2019[16]. - The net profit attributable to shareholders for 2020 was CNY 37,503,531.51, a decrease of 39.15% from CNY 61,632,302.42 in 2019[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,834,417.52, down 22.81% from CNY 60,677,086.08 in the previous year[16]. - The net cash flow from operating activities was CNY 13,495,800.83, a significant decline of 79.25% compared to CNY 65,027,238.40 in 2019[16]. - The basic earnings per share for 2020 was CNY 0.06, a decrease of 40.00% from CNY 0.10 in 2019[16]. - The diluted earnings per share for 2020 was CNY 0.06, a decrease of 40.00% compared to CNY 0.10 in 2019[17]. - The weighted average return on equity was 4.15%, down from 7.11% in the previous year, reflecting a decline of 2.96%[17]. - Total assets at the end of 2020 amounted to CNY 1,140,012,121.38, a slight increase of 0.13% from CNY 1,138,495,537.52 at the end of 2019[17]. - Net assets attributable to shareholders increased by 3.56% to CNY 912,050,796.35 from CNY 880,710,870.48 in 2019[17]. - The company reported a significant decrease in cash flow, indicating potential challenges in operational efficiency[16]. Dividend Policy - The company plans to distribute a cash dividend of CNY 0.1 per 10 shares to all shareholders, based on a total of 616,360,564 shares[5]. - The cash dividend amount distributed was CNY 6,163,605.64, which accounted for 100% of the total profit distribution[89]. - The cash dividend distribution plan is based on the undistributed profits as of December 31, 2020, amounting to CNY 138,754,933.58[89]. - The total number of shares for the cash dividend distribution in 2020 was based on 616,360,564 shares, with no stock dividends or capital reserve transfers[86]. - The company has implemented a cash dividend policy, distributing a cash dividend of 0.10 yuan per 10 shares for both 2019 and 2020, maintaining shareholder rights[85][86]. Business Strategy and Operations - The company continues to focus on high-tech product development and production, as well as the production of traditional Chinese and Western medicines[15]. - The company is focusing on optimizing its business structure and enhancing its operational management to adapt to changes in the pharmaceutical industry[24]. - The company aims to expand its market presence by promoting its flagship product, Sanqi Tongshu Capsule, and enhancing its brand recognition[24]. - The company is advancing the registration project for Sanqi Tongshu capsules in the EU and has published research on its anti-platelet aggregation mechanism[52]. - The company plans to establish a "three-in-one" chain clinic model integrating medical services, aesthetic medicine, and health products[76]. - The company is developing a stem cell application research center in collaboration with research institutions and universities[76]. - The company aims to achieve a net profit not lower than 120% of the 2019 level for 2020[77]. - The company is focusing on building a regional health industry ecosystem centered around major urban clusters in China[75]. - The company will continue to promote and complete the non-public stock issuance to leverage its platform advantages for business expansion and R&D enhancement[78]. Research and Development - The company holds 28 invention patents, including 4 international patents, and has made significant advancements in research and development[29]. - The company is focused on expanding its product range and improving product quality to enhance sales and market presence[34]. - The company plans to increase R&D investment in biomedicine, modern traditional Chinese medicine, and stem cell fields, aiming to enhance product competitiveness and expand its product pipeline[78]. - The number of R&D personnel increased by 23.85% to 161 in 2020 from 130 in 2019[53]. - Total R&D investment amounted to ¥26.87 million in 2020, down 8.99% from ¥29.53 million in 2019[54]. - Research and development expenses increased by 20%, totaling 150 million yuan, focusing on biotechnology innovations[166]. Market Performance - The pharmaceutical manufacturing segment experienced a revenue decline of 12.72%, totaling CNY 565.53 million, due to the impact of COVID-19 on hospital operations[35]. - The construction steel structure business saw a significant revenue increase of 110.28%, reaching CNY 178.15 million, driven by enhanced market expansion efforts[35]. - The sales volume of traditional Chinese and Western medicine products decreased by 20.47%, totaling 20,552,578 boxes in 2020 compared to 25,841,925 boxes in 2019[42]. - The company reported a decrease in overall gross margin by 8.74 percentage points due to changes in revenue structure[35]. - The company achieved a total revenue of CNY 759.31 million, representing a year-on-year growth of 1.87%[77]. Corporate Governance - The company has engaged in over 315 investor communications during the reporting period, addressing inquiries primarily related to production and operations[82]. - The company emphasizes the importance of creating an innovative atmosphere and enhancing employee value creation to support its development[79]. - The company has established a robust internal control system to improve management and risk prevention capabilities[178]. - The independent directors of the company attended 5 board meetings, with 2 in person and 3 by proxy, and attended 1 shareholders' meeting[183]. - The company reported no objections raised by independent directors regarding company matters during the reporting period[184]. - The company has a structured approach to governance, with clear roles for independent directors and supervisors[169]. Environmental and Social Responsibility - The company donated a total of 5.1632 million yuan to support social efforts against the COVID-19 pandemic, earning recognition as a "Most Caring Enterprise" by the Sichuan Red Cross[131]. - The company reported a total of 5.46 tons/year of COD emissions from wastewater, which is below the regulatory limit of 21.11 tons/year[132]. - The company achieved a 75% reduction in nitrogen oxide emissions following the boiler low-nitrogen transformation completed in 2019[133]. - The company has established a comprehensive wastewater treatment system and a corresponding exhaust gas treatment system, both of which are operating normally[133]. - The company is focusing on sustainability initiatives, with plans to reduce carbon emissions by 30% by 2025[160]. Shareholder Information - The total number of shareholders at the end of the reporting period was 40,646[144]. - The largest shareholder, Sichuan Huasheng Group Co., Ltd., holds 18.08% of the shares, totaling 111,431,281 shares[144]. - The report indicates that there were no changes in the number of shares held by the top 10 shareholders during the reporting period[146]. - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[146]. - The company has not issued any new shares or conducted any stock splits during the reporting period[143]. Management and Personnel - The total remuneration for directors, supervisors, and senior management in 2020 amounted to 3.6281 million yuan (pre-tax), with independent directors receiving a total of 283,300 yuan (pre-tax) in allowances[171]. - The company has a total of 13 current directors, supervisors, and senior management, with 26 individuals receiving remuneration during the reporting period[171]. - The company emphasizes a people-oriented approach in its compensation policy, aiming to align salaries with business performance and employee contributions[174]. - The company is committed to continuous employee training to enhance capabilities and optimize performance[175]. - The total number of employees in the company is 707, with 369 in the parent company and 338 in major subsidiaries[173].

Financial Performance - The company's operating revenue for Q1 2021 was ¥148,511,424.02, representing a 14.92% increase compared to ¥129,229,750.18 in the same period last year[7]. - Net profit attributable to shareholders was ¥11,715,714.45, an increase of 82.76% from ¥6,410,500.38 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥13,899,723.69, up 31.91% from ¥10,536,884.02 in the previous year[7]. - Total operating revenue for Q1 2021 was ¥148,511,424.02, an increase of 14.87% compared to ¥129,229,750.18 in the previous period[40]. - Net profit for Q1 2021 reached ¥11,865,391.51, representing a 85.66% increase from ¥6,410,500.38 in the same period last year[41]. - Operating profit for Q1 2021 was ¥15,539,049.78, a slight increase of 9.43% compared to ¥14,199,590.39 in the previous period[41]. - The company reported a total profit of ¥15,552,423.31 for Q1 2021, which is a 70.56% increase from ¥9,117,563.50 in the previous period[41]. Cash Flow - The net cash flow from operating activities was -¥57,536,200.29, a decrease of 203.44% compared to -¥18,961,142.53 in the same period last year[7]. - The net cash flow from operating activities recorded a deficit of CNY 57.54 million, an increase in deficit of CNY 38.58 million year-on-year, driven by increased cash receipts from sales and higher payments for raw materials and labor[16]. - Total cash inflow from operating activities was 195,544,500.14 CNY, while cash outflow was 253,080,700.43 CNY, resulting in a net cash outflow of 57,536,200.29 CNY[49]. - The company experienced a net decrease in cash and cash equivalents of -144,907,087.00 CNY in Q1 2021, compared to -17,040,920.41 CNY in Q1 2020[51]. - The total cash outflow for operating activities was 253,080,700.43 CNY, which is an increase of approximately 53% compared to the previous year's outflow of 165,677,426.67 CNY[49]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,177,794,235.13, a 3.31% increase from ¥1,140,012,121.38 at the end of the previous year[7]. - Total liabilities increased to CNY 253,475,321.57 from CNY 227,558,599.33, reflecting a growth of about 11.4%[34]. - Current liabilities rose to CNY 221,571,216.37 from CNY 214,089,643.51, marking an increase of approximately 3.5%[34]. - The company's long-term equity investments increased to CNY 217,490,000.00 from CNY 167,490,000.00, representing a growth of 29.9%[37]. - The company's retained earnings increased to CNY 150,470,648.03 from CNY 138,754,933.58, an increase of approximately 8.8%[35]. Investments and Expenditures - The company established a new subsidiary, Hainan Huasheng Development Holdings Group Co., Ltd., incurring costs of ¥15,291,700 for office building purchases and land auction deposits[15]. - Cash and cash equivalents decreased by 35.76% to ¥14,488.73 million, primarily due to investments in new business developments[15]. - Net cash flow from investing activities showed a deficit of CNY 87.37 million, a decrease in deficit of CNY 89.29 million year-on-year, mainly due to prepayments and deposits for office buildings and land purchases in Hainan by subsidiary Hainan Huashen Development Holding Group[16]. - Cash outflow from investment activities was 92,165,926.86 CNY, compared to only 37,600.00 CNY in the same period last year[50]. Operational Metrics - The basic earnings per share increased to ¥0.02, doubling from ¥0.01 in the previous year[7]. - The weighted average return on net assets was 1.28%, up from 0.73% year-on-year[7]. - Research and development expenses for Q1 2021 were ¥2,063,937.22, down 33.51% from ¥3,103,927.14 in the previous period[40]. - Sales expenses for Q1 2021 were ¥57,150,934.85, a decrease of 11.43% compared to ¥64,372,523.96 in the previous period[40]. - The company experienced a foreign exchange loss of ¥2,084,538.00 in Q1 2021[40].